Mumbai, Nov. 26 -- Albumin is in high demand for various medical treatments, including restoring blood volume and replacing lost fluids during accidents, serious burn injuries, fatal erythroblastosis, hypoproteinemia, and surgeries. However, the supply of human serum albumin is limited due to the reliance on whole blood or donated human plasma. Shilpa's Recombinant Human Albumin 20% (rHA), derived from yeast, offers a highly purified, structurally and functionally equivalent alternative to human serum albumin.

The company has successfully completed its Phase I clinical trials on 7 August 2024. With today's announcement, the company confirms that the SEC has accepted the trial results and approved the progression to Phase III trials for r...